Spyre Therapeutics (SYRE) Proxy filing summary

Executive summary

• The annual meeting is scheduled for May 27, 2026, with voting on director elections, executive compensation, auditor ratification, and an amended employee stock purchase plan.

• The board recommends voting in favor of all proposals, including the election of three Class I directors and approval of the amended ESPP.

• The company advanced its clinical programs, expanded its pipeline, and raised over $310 million in 2025.

• Proxy materials are primarily distributed electronically to reduce costs and environmental impact.

Voting matters and shareholder proposals

• Proposals include electing three Class I directors, a non-binding advisory vote on executive compensation, ratification of KPMG LLP as auditor, and approval of the amended 2016 Employee Stock Purchase Plan.

• The board recommends voting FOR all proposals.

• Shareholders may submit proposals for the 2027 meeting by December 11, 2026.

Board of directors and corporate governance

• The board consists of eight directors divided into three classes with staggered three-year terms.

• The board has Audit, Compensation, and Nominating Committees, all composed of independent directors.

• The board annually evaluates governance structure and values input from shareholders.

• Board diversity and director time commitments are emphasized, with limits on outside board service.

• The chair and CEO roles are currently separated, with an independent chair.